Lantern files for IPO to study 5-time phase 3 cancer failure

Lantern Pharma has filed IPO paperwork to raise money to test a failed cancer prospect. The drug, LP-300, failed five phase 3 trials between 2006 and 2013, but retrospective analyses of data from two of the studies have convinced Lantern it has a future in a subset of lung cancer patients.